111
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: not found
          • Article: not found

          A Confidence Interval for the Median Survival Time

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Current standards for clinical management of small cell lung cancer

            Small cell lung cancer (SCLC) is an aggressive high-grade neuroendocrine carcinoma. Despite over 30 years of clinical research, little progress has been made in the management of SCLC, and outcomes remain poor. Here, we review the current clinical standards for management of SCLC and the data supporting these strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)

              The aim of this study was to assess the efficacy of maintenance pembrolizumab in patients with extensive-stage SCLC after treatment with platinum and etoposide.
                Bookmark

                Author and article information

                Journal
                New England Journal of Medicine
                N Engl J Med
                New England Journal of Medicine (NEJM/MMS)
                0028-4793
                1533-4406
                September 25 2018
                September 25 2018
                Affiliations
                [1 ]From Vanderbilt University Medical Center (L. Horn) and Sarah Cannon Research Institute–Tennessee Oncology (M.L.J.), Nashville; Mayo Clinic, Rochester, MN (A.S.M.); Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock (A. Szczęsna), and Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie, Warsaw (M.K.) — both in Poland; Thomayerova Nemocnice, Pneumologická Klinika 1.LF UK, Prague, Czech Republic (L. Havel); the Department of Respiratory and Critical Care Medicine (M.J.H.) and the...
                Article
                10.1056/NEJMoa1809064
                aef4af81-34de-48bf-8d46-862c25076cef
                © 2018

                http://www.nejmgroup.org/legal/terms-of-use.htm

                History

                Comments

                Comment on this article